Kevin Strauss to Genetic Therapy
This is a "connection" page, showing publications Kevin Strauss has written about Genetic Therapy.
Connection Strength
1.965
-
Wang J, Turgeon CT, Loken PR, Gray-Edwards H, Gao G, Tortorelli S, Wang D, Strauss KA. Systemic dual-gene therapy reverses biochemical intoxication in the central metabolic compartment of Bckdha-/- mice. Mol Ther. 2026 Aug 05; 34(8):4569-4580.
Score: 0.568
-
Brigatti KW, Rodrigues A, Sweigert E, Williamson J, Koehler A, Meier GL, Poskitt LE, Carson VJ, Robinson D, Strauss KA. Trial-ready external controls for gene therapy: The MATCH cohort in maple syrup urine disease. Cell Rep Med. 2026 Jun 16; 7(6):102799.
Score: 0.568
-
Matesanz SE, Brigatti KW, Young M, Yum SW, Strauss KA. Preemptive dual therapy for children at risk for infantile-onset spinal muscular atrophy. Ann Clin Transl Neurol. 2024 07; 11(7):1868-1878.
Score: 0.497
-
Wang J, Poskitt LE, Gallagher J, Puffenberger EG, Wynn RM, Shishodia G, Chuang DT, Beever J, Hardin DL, Brigatti KW, Baker WC, Gately R, Bertrand S, Rodrigues A, Benatti HR, Taghian T, Hall E, Prestigiacomo R, Liang J, Chen G, Zhou X, Ren L, Liu N, He R, Su Q, Xie J, Jiang Z, Gruntman A, Gray-Edwards H, Gao G, Strauss KA, Wang D. BCKDHA-BCKDHB digenic gene therapy restores metabolic homeostasis in two mouse models and a calf with classic maple syrup urine disease. Sci Transl Med. 2025 Feb 26; 17(787):eads0539.
Score: 0.131
-
Day JW, Mendell JR, Mercuri E, Finkel RS, Strauss KA, Kleyn A, Tauscher-Wisniewski S, Tukov FF, Reyna SP, Chand DH. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Drug Saf. 2021 10; 44(10):1109-1119.
Score: 0.102
-
Yang H, Brown RH, Wang D, Strauss KA, Gao G. AAV-Mediated Gene Therapy for Glycosphingolipid Biosynthesis Deficiencies. Trends Mol Med. 2021 06; 27(6):520-523.
Score: 0.099